)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Inhalation Sciences
Inhalation Sciences (ISAB) investor relations material
Inhalation Sciences Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary11 May, 2026
Executive summary
Revenue and order intake surged significantly year-over-year, driven by execution of a strong order backlog from Q4 2025 and successful conversion of pipeline opportunities.
Active process underway to explore potential acquisition of the business, with ongoing discussions via PharmaVentures and a target to conclude before summer 2026.
Continued engagement with the FDA regarding publication of the Dissolvit project, aiming for publication within 2026.
Financial highlights
Net revenue for Q1 2026 was 4,147 tkr, up from 809 tkr in Q1 2025.
Operating result improved to -1,400 tkr from -2,241 tkr year-over-year.
Earnings per share (EPS) was -0.04 SEK, compared to -0.15 SEK in Q1 2025.
Order intake reached 2,420 tkr, up from 908 tkr in the prior year period.
Cash flow from operations was -1,245 tkr, unchanged from Q1 2025.
Outlook and guidance
Commercialization efforts are expanding, with new modules and services in development to broaden the product and service portfolio.
The acquisition process is expected to conclude within 9-12 months, aiming to maximize shareholder value.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Inhalation Sciences
- Order intake rose sharply in Q4, but sales and earnings declined; strategic review underway.ISAB
Q4 202527 Feb 2026 - Operating profit up 24% in H1 2024, but sales and order intake declined; FDA study nears completion.ISABQ2 202423 Jan 2026
- Operating profit up 12% despite lower sales; FDA study and partnerships support outlook.ISABQ3 202413 Jan 2026
- Revenue fell, losses widened, but order intake and cash position improved after new financing.ISABQ3 202521 Nov 2025
- FDA validation of Dissolvate positions the company as a leader in inhalation drug research services.ISABStudy Result12 Nov 2025
- Revenue fell sharply, but cost cuts and new funding support a push toward profitability.ISABQ2 202529 Aug 2025
- Record order backlog and FDA validation drive growth plans despite widening losses.ISABQ1 20256 Jun 2025
- Revenue fell and losses widened in 2024, with growth hinging on new sales and financing.ISABQ4 20245 Jun 2025
Next Inhalation Sciences earnings date
Q2 202621 Aug, 2026
Inhalation Sciences
Next Inhalation Sciences earnings date
Q2 202621 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage